Adenocarcinoma 
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adenocarcinoma
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Recruiting
2
80
Europe
Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications
Pancreatic Neuroendocrine Carcinoma
10/23
10/23
NCT00655252 / 2007-005460-28: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Checkmark RCC
Jan 2013 - Jan 2013: RCC
Checkmark Data - ESMO 2012
Sep 2012 - Sep 2012: Data - ESMO 2012
Checkmark Data -ESMO 2012
More
No Longer Available
N/A
US, Canada, Europe, RoW
Everolimus
Novartis Pharmaceuticals
Metastatic Renal Cell Cancer
 
 
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

No Longer Available
N/A
Canada, RoW
Axitinib, AG-013736
Pfizer
Renal Cell Carcinoma
03/14
03/14
NCT02082691: Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

No Longer Available
N/A
US
G-202
Devalingam Mahalingam, GenSpera, Inc.
Hepatocellular Carcinoma
 
 
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

No Longer Available
N/A
US
Brigatinib, AP26113
Ariad Pharmaceuticals
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
 
 

Download Options